Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Elosulfase alfa (BMN 110), a recombinant human N-acetylgalactosamine-6-sulfatase (GALNS), serves as enzyme replacement therapy for mucopolysaccharidosis IVA (MPS IVA), commonly referred to as Morquio A syndrome [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Elosulfase alfa (BMN 110), a recombinant human N-acetylgalactosamine-6-sulfatase (GALNS), serves as enzyme replacement therapy for mucopolysaccharidosis IVA (MPS IVA), commonly referred to as Morquio A syndrome [1]. |
Synonyms | Chondrosulfatase, Chondrosulfatases, BMN 110, Chondroitinase, Chondroitin sulfatase |
Molecular Weight | N/A |
CAS No. | 9025-60-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Elosulfase alfa 9025-60-9 Chondrosulfatase Chondrosulfatases BMN 110 Chondroitinase Chondroitin sulfatase inhibitor inhibit